Skip to content
10-Q

Quarterly Report

SYROS PHARMACEUTICALS, INC.

0000950170-23-039337

← back to feed
Filed
Aug 8, 2023 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2023 · Aug 4, 2023 20.71M sh
Long Term Debt Q2 2023 · Jun 30, 2023 $40.93M
Long Term Debt Q2 2023 · Dec 31, 2022 $40.65M
Current Liabilities Q2 2023 · Jun 30, 2023 $28.38M
Current Liabilities Q2 2023 · Dec 31, 2022 $30.78M
Current Assets Q2 2023 · Jun 30, 2023 $152.63M
Current Assets Q2 2023 · Dec 31, 2022 $211.39M
Total Assets Q2 2023 · Jun 30, 2023 $180.98M
Total Assets Q2 2023 · Dec 31, 2022 $244.49M
Cash And Equivalents Q2 2023 · Dec 31, 2022 $167.47M
Cash And Equivalents Q2 2023 · Jun 30, 2022 $59.06M
Shares Diluted restated Q2 2023 · Jun 30, 2022 6.38M sh
Shares Diluted restated Q2 2023 · Jun 30, 2022 6.34M sh
Capex Q2 2023 · Jun 30, 2022 $239K
Operating Cash Flow Q2 2023 · Jun 30, 2022 −$56.2M
Stockholders Equity Q2 2023 · Jun 30, 2022 $31.02M
Stockholders Equity Q2 2023 · Mar 31, 2022 $62.74M
Stockholders Equity Q2 2023 · Dec 31, 2021 $85.22M
Eps Diluted restated Q2 2023 · Jun 30, 2022 −$5.40
Eps Diluted restated Q2 2023 · Jun 30, 2022 −$9.40
Eps Basic restated Q2 2023 · Jun 30, 2022 −$5.40
Eps Basic restated Q2 2023 · Jun 30, 2022 −$9.40
Sga Expense Q2 2023 · Jun 30, 2022 $6.95M
Sga Expense Q2 2023 · Jun 30, 2022 $13.89M
Rd Expense Q2 2023 · Jun 30, 2022 $33.1M
Rd Expense Q2 2023 · Jun 30, 2022 $58.27M
Net Income Q2 2023 · Jun 30, 2022 −$34.48M
Net Income Q2 2023 · Jun 30, 2022 −$59.63M
Operating Income Q2 2023 · Jun 30, 2022 −$33.77M
Operating Income Q2 2023 · Jun 30, 2022 −$60.42M
Revenue Q2 2023 · Jun 30, 2022 $6.28M
Revenue Q2 2023 · Jun 30, 2022 $11.74M